Pneumovax 23 Market Expected To Grow At % CAGR Through 2030: What Businesses Need To Know
Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Pneumovax 23 Market CAGR Outlook And Future Development
Historical growth has been driven by the broadening of national immunization programs, a greater frequency of pneumococcal infections among older individuals, the accessibility of polysaccharide-based vaccines, an increase in preventative health efforts, and heightened public knowledge about vaccination.
The anticipated expansion during the forecast period is propelled by heightened financial commitments to adult vaccination initiatives, an intensified emphasis on preventing infectious diseases, the broadening availability of immunization services through pharmacies, the escalating need for prolonged vaccine efficacy, and innovations in vaccine storage and distribution.
Prominent developments anticipated for the forecast duration encompass an elevated concentration on immunization programs for adults and the elderly, a surging requirement for protection against pneumococcal disease, the increasing implementation of proactive vaccination approaches, the enlargement of public health immunization efforts, and improved management of the cold chain for vaccines.
Get A Free Sample Report With In-Depth Market Insights:
Pneumovax 23 Market Demand Drivers: What’s Powering Industry Growth?
The escalating occurrence of pneumococcal diseases is anticipated to fuel the expansion of the pneumovax 23 market in the coming years. Pneumococcal diseases are infections caused by the bacterium *Streptococcus pneumoniae*, also known as pneumococcus, which can result in various health conditions, from mild issues like sinusitis and otitis media to severe ailments such as pneumonia and meningitis, often necessitating hospitalization. The rise in pneumococcal disease cases can be linked to factors including reduced vaccination coverage during the COVID-19 pandemic, heightened susceptibility among individuals with chronic health conditions, and a rebound of respiratory infections following the relaxation of social restrictions. Pneumovax 23 aids in preventing pneumococcal diseases by providing immunity against 23 strains of *Streptococcus pneumoniae*, thereby lowering the risk of infections like pneumonia, meningitis, and bacteremia. For instance, in June 2025, the Office for Health Improvement and Disparities, a UK-based government body, reported that emergency hospital admissions for pneumonia in England increased by 16% in the financial year ending 2024 compared to the previous year, reaching a rate of 430 per 100,000 people and totaling approximately 252,912 admissions. Hence, the increasing global incidence of pneumococcal diseases is a key driver for the growth of the pneumovax 23 market.
Pneumovax 23 Market Segment Breakdown: Which Categories Lead On Revenue?
The pneumovax 23 market covered in this report is segmented –
1) By Formulation: Pneumococcal Polysaccharide Vaccine (PPV), Pneumococcal Conjugate Vaccine (PCV)
2) By Clinical Indication: Pneumococcal Disease Prevention
3) By End User: Hospitals, Clinics, Ambulatory Surgical Centers, Pharmacies
Pneumovax 23 Market Leading Players And Competitive Positioning
Major companies operating in the pneumovax 23 market are Merck & Co. Inc. (Merck Sharp & Dohme Corp.)
View The Full Pneumovax 23 Market Report:
Pneumovax 23 Market Largest Region By Revenue And Market Share
North America was the largest region in the pneumovax 23 market in 2025. The regions covered in the pneumovax 23 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
